Shanghai Yizhong Pharmaceutical Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shanghai Yizhong Pharmaceutical Co., Ltd.

Why is Shanghai Yizhong Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 196.91% and Operating profit at 48.07% over the last 5 years

The company has declared Negative results for the last 5 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at CNY -5.77 MM
DEBT-EQUITY RATIO (HY) Highest at 0 %
DEBTORS TURNOVER RATIO(HY) Lowest at 0 times

With ROE of 0.29%, it has a very expensive valuation with a 8.35 Price to Book Value

Over the past year, while the stock has generated a return of 12.49%, its profits have fallen by -95.4%
At the current price, the company has a high dividend yield of 0

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Shanghai Yizhong Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shanghai Yizhong Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Shanghai Yizhong Pharmaceutical Co., Ltd.

32.89%

1.58

57.47%

China Shanghai Composite

20.36%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

196.91%

EBIT Growth (5y)

48.07%

EBIT to Interest (avg)

80.83

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.43

Sales to Capital Employed (avg)

0.18

Tax Ratio

39.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

32.26%

ROE (avg)

7.02%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

173

Industry P/E

Price to Book Value

7.65

EV to EBIT

228.72

EV to EBITDA

201.17

EV to Capital Employed

7.65

EV to Sales

34.51

PEG Ratio

Dividend Yield

ROCE (Latest)

3.35%

ROE (Latest)

4.42%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

24What is working for the Company

NET SALES(HY)

At CNY 152.11 MM has Grown at 103.46%

NET PROFIT(HY)

Higher at CNY 32.68 MM

RAW MATERIAL COST(Y)

Fallen by -5.35% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 1.06 times

-6What is not working for the Company

INTEREST(HY)

At CNY 0.11 MM has Grown at 9,462.19%

DEBT-EQUITY RATIO (HY)

Highest at -27.15 %

Here's what is working for Shanghai Yizhong Pharmaceutical Co., Ltd.

Net Sales

At CNY 152.11 MM has Grown at 103.46%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (CNY MM)

Net Profit

At CNY 32.68 MM has Grown at 260.12%

Year on Year (YoY)

MOJO Watch

Net Profit trend is very positive

Net Profit (CNY MM)

Net Profit

Higher at CNY 32.68 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Inventory Turnover Ratio

Highest at 1.06 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -5.35% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai Yizhong Pharmaceutical Co., Ltd.

Interest

At CNY 0.11 MM has Grown at 9,462.19%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at -27.15 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio